NL7306978A - - Google Patents

Info

Publication number
NL7306978A
NL7306978A NL7306978A NL7306978A NL7306978A NL 7306978 A NL7306978 A NL 7306978A NL 7306978 A NL7306978 A NL 7306978A NL 7306978 A NL7306978 A NL 7306978A NL 7306978 A NL7306978 A NL 7306978A
Authority
NL
Netherlands
Application number
NL7306978A
Other versions
NL177493B (nl
NL177493C (nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20269234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL7306978(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NL7306978A publication Critical patent/NL7306978A/xx
Publication of NL177493B publication Critical patent/NL177493B/xx
Application granted granted Critical
Publication of NL177493C publication Critical patent/NL177493C/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NLAANVRAGE7306978,A 1972-05-19 1973-05-18 Werkwijze voor de bereiding van steroiden en werkwijze ter bereiding van een farmaceutisch preparaat tegen ontstekingen. NL177493C (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206644A SE378109B (index.php) 1972-05-19 1972-05-19

Publications (3)

Publication Number Publication Date
NL7306978A true NL7306978A (index.php) 1973-11-21
NL177493B NL177493B (nl) 1985-05-01
NL177493C NL177493C (nl) 1985-10-01

Family

ID=20269234

Family Applications (2)

Application Number Title Priority Date Filing Date
NLAANVRAGE7306978,A NL177493C (nl) 1972-05-19 1973-05-18 Werkwijze voor de bereiding van steroiden en werkwijze ter bereiding van een farmaceutisch preparaat tegen ontstekingen.
NL930025C NL930025I1 (nl) 1972-05-19 1993-04-13 Werkwijze voor de bereiding van steroïden en werkwijze ter bereiding van een farmaceutisch preparaattegen ontstekingen

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL930025C NL930025I1 (nl) 1972-05-19 1993-04-13 Werkwijze voor de bereiding van steroïden en werkwijze ter bereiding van een farmaceutisch preparaattegen ontstekingen

Country Status (26)

Country Link
US (2) US3929768A (index.php)
JP (1) JPS5521760B2 (index.php)
AT (1) AT328630B (index.php)
BE (1) BE799727A (index.php)
CA (1) CA1002938A (index.php)
CH (1) CH595400A5 (index.php)
CS (1) CS178129B2 (index.php)
CY (1) CY1013A (index.php)
DD (1) DD104295A5 (index.php)
DE (1) DE2323215C3 (index.php)
DK (1) DK134783B (index.php)
ES (1) ES414673A1 (index.php)
FI (1) FI50631C (index.php)
FR (1) FR2185405B1 (index.php)
GB (1) GB1429922A (index.php)
HK (1) HK49179A (index.php)
HU (1) HU166680B (index.php)
IL (1) IL42155A (index.php)
KE (1) KE2970A (index.php)
NL (2) NL177493C (index.php)
NO (2) NO139640C (index.php)
PL (1) PL87765B1 (index.php)
SE (1) SE378109B (index.php)
SU (1) SU470954A3 (index.php)
YU (1) YU35896B (index.php)
ZA (1) ZA732955B (index.php)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004580L (sv) * 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8403905D0 (sv) * 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
SE8501693D0 (sv) * 1985-04-04 1985-04-04 Draco Ab Novel 16,17-acetalsubstituted androstane-17beta-carboxylic acid esters
US5215979A (en) * 1985-12-19 1993-06-01 Aktiebolaget Draco 16,17-acetalsubstituted pregnane 21-oic acid derivatives
SE8506015D0 (sv) * 1985-12-19 1985-12-19 Draco Ab Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
LV5274A3 (lv) * 1988-02-29 1993-10-10 Richter Gedeon Vegyeszet 22(R,S)-11 beta,21-dihidroksi-16 alpha,17-butilidenbisoksipregna-1,4-dien-3,20-diona iegusanas panemiens
HU203769B (en) * 1989-03-09 1991-09-30 Richter Gedeon Vegyeszet Process for producing new steroide derivatives and pharmaceutical compositions containing them
SE8903219D0 (sv) * 1989-10-02 1989-10-02 Astra Ab Process for the manufacture of budesonide
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
FR2675146A1 (fr) * 1991-04-10 1992-10-16 Roussel Uclaf Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires.
MD24C2 (ro) * 1991-07-09 1994-05-31 Fabrica De Parfumerii Si Cosmetica "Viorica" Compoziţie de substanţe odorante
LT3695B (en) 1991-11-18 1996-02-26 Dineika Raimundas Arnas Folded roof
CA2123909C (en) * 1991-12-18 2002-10-01 Christer Carl Gustav Carling New combination of formoterol and budesonide
HUT72442A (en) * 1992-12-24 1996-04-29 Rhone Poulenc Rorer Ltd Steroids condensed with heteroring containing oxygene, pharmaceutical compositions containing them and processes for their production
SK87295A3 (en) * 1993-01-08 1996-04-03 Astra Ab Novel colon or ileum-specific steroid derivatives
HU220868B1 (en) 1993-04-02 2002-06-29 Byk Gulden Lomberg Chem Fab New prednisolone derivative, process for its production, use of the same and pharmaceutical composition containing the same
GB9423919D0 (en) * 1994-11-26 1995-01-11 Rhone Poulenc Rorer Ltd Chemical process
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
DE29717252U1 (de) * 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
CA2372720C (en) 1999-05-04 2007-09-11 John Antony Kanis Androgen glycosides and androgenic activity thereof
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009613D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
AU2003291634A1 (en) * 2002-10-08 2004-05-04 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
MXPA05011225A (es) * 2003-04-18 2005-12-14 Pharmacia & Upjohn Co Llc Politerapias.
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1663999A2 (en) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitors of phosphodiesterase type-iv
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
AU2005233569B2 (en) 2004-04-09 2010-08-19 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
CA2626628A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
JP2009512733A (ja) * 2005-11-02 2009-03-26 シコール インコーポレイティド シクレソニドの改良された製造法
AR059216A1 (es) 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
NZ574905A (en) * 2006-08-22 2011-12-22 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CN101616901A (zh) * 2006-09-22 2009-12-30 兰贝克赛实验室有限公司 Iv型磷酸二酯酶的抑制剂
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2674084C (en) 2006-12-26 2013-05-14 Pharmacyclics, Inc. Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US10201490B2 (en) 2007-02-14 2019-02-12 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases
EP1958639A1 (en) 2007-02-14 2008-08-20 Polichem S.A. Use of chitosans for the treatment of nail inflammatory diseases
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
PL2124944T3 (pl) 2007-03-14 2012-08-31 Sun Pharmaceutical Ind Ltd Pochodne pirazolo[3,4-b]pirydyny jako inhibitory fosfodiesterazy
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090082319A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched budesonide
US8796248B2 (en) 2007-10-05 2014-08-05 Nektar Therapeutics Oligomer-corticosteroid conjugates
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
US20100331539A1 (en) * 2008-03-13 2010-12-30 Farmabios S.P.A. Process for the preparation of pregnane derivatives
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
CN101279997B (zh) * 2008-05-29 2011-08-24 鲁南制药集团股份有限公司 布地奈德的一种制备方法
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SMT202000077T1 (it) 2009-05-29 2020-03-13 Pearl Therapeutics Inc Composizioni per il rilascio polmonare di antagonisti muscarinici a lunga durata e agonisti dei recettori beta-2 adrenergici a lunga durata e metodi e sistemi associati
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
LT2482822T (lt) 2009-10-01 2018-09-10 Adare Pharmaceuticals, Inc. Geriamosios kortikosteroidų kompozicijos
AU2010307198B9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011093812A2 (en) 2010-01-28 2011-08-04 Mahmut Bilgic Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
EP2534145A4 (en) 2010-02-08 2013-09-11 Kinagen Inc THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE
CN101863952B (zh) * 2010-04-30 2013-04-17 湖北葛店人福药业有限责任公司 布地奈德的制备方法
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CN103282497B (zh) 2010-08-17 2018-07-10 瑟纳治疗公司 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
MX365393B (es) 2011-09-13 2019-05-31 Pharmacyclics Llc Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas.
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013109214A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Process for the preparation of dry powder formulations
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN103421075B (zh) * 2012-05-16 2017-07-28 上海特化医药科技有限公司 孕烷衍生物16,17‑缩醛(酮)的制备方法
WO2014007781A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
WO2014007770A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising corticosteroid and sorbitol
NZ704799A (en) 2012-08-24 2018-06-29 Univ Texas Heterocyclic modulators of hif activity for treatment of disease
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
JP6290237B2 (ja) 2012-11-28 2018-03-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための組成物および方法
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2014144894A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
EP2999460A1 (en) 2013-05-22 2016-03-30 Pearl Therapeutics, Inc. Compositions, methods&systems for respiratory delivery of three or more active agents
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10233210B2 (en) 2015-01-30 2019-03-19 Coral Drugs Pvt. Ltd. Process for preparation of glucocorticoid steroids
EP3475275B1 (en) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP4659809A2 (en) 2016-11-08 2025-12-10 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
US11491237B2 (en) 2017-05-18 2022-11-08 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
MX2020004691A (es) 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CN112004557B (zh) 2018-01-08 2024-07-30 里珍纳龙药品有限公司 类固醇类化合物及其抗体偶联物
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
KR20210046009A (ko) 2018-08-07 2021-04-27 머크 샤프 앤드 돔 코포레이션 Prmt5 억제제
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
WO2021126728A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2021126729A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3160153A1 (en) 2019-12-17 2021-06-24 Michelle Machacek Prmt5 inhibitors
PL4175620T3 (pl) 2021-07-09 2024-08-05 Astrazeneca Pharmaceuticals Lp Kompozycje, sposoby i systemy do dostarczania leków w aerozolu
JP2024545816A (ja) 2021-12-20 2024-12-12 アストラゼネカ・アクチエボラーグ エアロゾル薬物送達のための組成物、方法及びシステム
WO2024049931A1 (en) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
PE20251547A1 (es) 2022-10-25 2025-06-05 Merck Sharp And Dohme Llc Enlazadores-cargas utiles de adc derivados de exatecan, composiciones farmaceuticas, y usos de los mismos
EP4633681A1 (en) 2022-12-14 2025-10-22 Merck Sharp & Dohme LLC Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) * 1964-03-24 Chioacyl
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US2990401A (en) * 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae
JPS4843910A (index.php) * 1971-10-08 1973-06-25

Also Published As

Publication number Publication date
NO139640B (no) 1979-01-08
IL42155A0 (en) 1973-07-30
ATA436573A (de) 1975-06-15
DE2323215C3 (de) 1978-03-30
JPS4941378A (index.php) 1974-04-18
NL177493B (nl) 1985-05-01
ES414673A1 (es) 1976-07-01
FR2185405A1 (index.php) 1974-01-04
FI50631C (fi) 1976-05-10
NO1994013I1 (no) 1994-08-31
AT328630B (de) 1976-03-25
GB1429922A (en) 1976-03-31
YU35896B (en) 1981-08-31
DK134783B (da) 1977-01-17
KE2970A (en) 1979-07-20
AU5525373A (en) 1974-11-07
JPS5521760B2 (index.php) 1980-06-12
FR2185405B1 (index.php) 1976-12-31
NL177493C (nl) 1985-10-01
SE378109B (index.php) 1975-08-18
SU470954A3 (ru) 1975-05-15
ZA732955B (en) 1974-04-24
HK49179A (en) 1979-07-27
CA1002938A (en) 1977-01-04
HU166680B (index.php) 1975-05-28
DD104295A5 (index.php) 1974-03-05
CY1013A (en) 1979-11-23
YU129173A (en) 1981-02-28
US3983233A (en) 1976-09-28
FI50631B (index.php) 1976-02-02
BE799727A (fr) 1973-09-17
NL930025I1 (nl) 1993-06-01
US3929768A (en) 1975-12-30
CS178129B2 (index.php) 1977-08-31
IL42155A (en) 1977-06-30
DE2323215B2 (de) 1977-08-11
CH595400A5 (index.php) 1978-02-15
PL87765B1 (index.php) 1976-07-31
NO139640C (no) 1979-04-18
DK134783C (index.php) 1977-06-06
DE2323215A1 (de) 1973-11-29

Similar Documents

Publication Publication Date Title
JPS5521760B2 (index.php)
BR7203119D0 (index.php)
CH582833A5 (index.php)
CH587055A5 (index.php)
BG17917A1 (index.php)
BG18077A1 (index.php)
BG18152A1 (index.php)
BG18347A1 (index.php)
CH583002A5 (index.php)
BG18477A1 (index.php)
BG19261A1 (index.php)
BG19449A1 (index.php)
CH334172A4 (index.php)
CH545900A (index.php)
CH560842A5 (index.php)
CH561007A5 (index.php)
CH561361A5 (index.php)
CH564568A5 (index.php)
CH565479A5 (index.php)
CH569243A5 (index.php)
CH569247A5 (index.php)
CH569740A5 (index.php)
CH570213A5 (index.php)
CH570606A5 (index.php)
CH572450A5 (index.php)

Legal Events

Date Code Title Description
BC A request for examination has been filed
CNR Transfer of rights (patent application after its laying open for public inspection)

Free format text: AKTIEBOLAGET DRACO

A85 Still pending on 85-01-01
AC1 Application for a supplementary protection certificate

Free format text: 930025, 930413

V4 Discontinued because of reaching the maximum lifetime of a patent
AC1 Application for a supplementary protection certificate

Free format text: 930025, 930413

BC1 Further communications concerning applications for a supplementary protection certificate

Free format text: 930025

AC1 Application for a supplementary protection certificate

Free format text: 930025, 930413

BC1 Further communications concerning applications for a supplementary protection certificate

Free format text: 930025